ALDX vs. XNCR, KROS, COGT, MRVI, RGLS, SVRA, KURA, STOK, ETON, and TYRA
Should you be buying Aldeyra Therapeutics stock or one of its competitors? The main competitors of Aldeyra Therapeutics include Xencor (XNCR), Keros Therapeutics (KROS), Cogent Biosciences (COGT), Maravai LifeSciences (MRVI), Regulus Therapeutics (RGLS), Savara (SVRA), Kura Oncology (KURA), Stoke Therapeutics (STOK), Eton Pharmaceuticals (ETON), and Tyra Biosciences (TYRA). These companies are all part of the "pharmaceutical preparations" industry.
Aldeyra Therapeutics vs.
Aldeyra Therapeutics (NASDAQ:ALDX) and Xencor (NASDAQ:XNCR) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, profitability, media sentiment, earnings, community ranking, risk, institutional ownership and valuation.
Aldeyra Therapeutics has higher earnings, but lower revenue than Xencor. Xencor is trading at a lower price-to-earnings ratio than Aldeyra Therapeutics, indicating that it is currently the more affordable of the two stocks.
Aldeyra Therapeutics currently has a consensus price target of $9.50, indicating a potential upside of 322.22%. Xencor has a consensus price target of $29.50, indicating a potential upside of 283.62%. Given Aldeyra Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Aldeyra Therapeutics is more favorable than Xencor.
Aldeyra Therapeutics has a net margin of 0.00% compared to Xencor's net margin of -232.77%. Xencor's return on equity of -30.92% beat Aldeyra Therapeutics' return on equity.
Xencor received 23 more outperform votes than Aldeyra Therapeutics when rated by MarketBeat users. Likewise, 73.13% of users gave Xencor an outperform vote while only 69.43% of users gave Aldeyra Therapeutics an outperform vote.
Aldeyra Therapeutics has a beta of 0.92, meaning that its stock price is 8% less volatile than the S&P 500. Comparatively, Xencor has a beta of 0.99, meaning that its stock price is 1% less volatile than the S&P 500.
59.7% of Aldeyra Therapeutics shares are owned by institutional investors. 9.6% of Aldeyra Therapeutics shares are owned by insiders. Comparatively, 4.8% of Xencor shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
In the previous week, Aldeyra Therapeutics had 10 more articles in the media than Xencor. MarketBeat recorded 16 mentions for Aldeyra Therapeutics and 6 mentions for Xencor. Xencor's average media sentiment score of 1.17 beat Aldeyra Therapeutics' score of 0.68 indicating that Xencor is being referred to more favorably in the news media.
Summary
Aldeyra Therapeutics and Xencor tied by winning 9 of the 18 factors compared between the two stocks.
Get Aldeyra Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ALDX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Aldeyra Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:ALDX) was last updated on 5/23/2025 by MarketBeat.com Staff
